Genomas Enters the CYP450-Testing Fray; Firm Hopes to Follow With Nutrigenomic Array | GenomeWeb

The increasingly crowded CYP450-testing market has one more occupant — Hartford, Conn.-based Genomas' Hilomet PhysioType. Although the test is not unique, the company hopes it will sell enough to support the release of at least two more genotyping tests in another of Genomas' core areas, nutritional genomics.

The test is valuable to Genomas as "an early revenue stream" that "gives us the experience we need as we introduce the more proprietary PhysioType systems that we're developing," Robert Scherrer, Genomas' CFO, told Pharmacogenomics Reporter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.